Obesity paradox in cancer: Is bigger really better?
Beata Ujvari, Camille Jacqueline, Dorothée Missé, Valentin Amar, Jay Fitzpatrick, Geordie Jennings, Christa Beckmann, Sophie Rome, Peter A. Biro, Robert Gatenby, et al.

To cite this version:
Beata Ujvari, Camille Jacqueline, Dorothée Missé, Valentin Amar, Jay Fitzpatrick, et al.. Obesity paradox in cancer: Is bigger really better?. Evolutionary Applications, 2019, 12 (6), pp.1092-1095. 10.1111/eva.12790 . hal-02433971

HAL Id: hal-02433971
https://hal.science/hal-02433971
Submitted on 26 Feb 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Obesity paradox in cancer: Is bigger really better?

Beata Ujvari1,2 | Camille Jacqueline3 | Dorothée Misse3 | Valentin Amar4 | Jay C. Fitzpatrick1 | Geordie Jennings1,2 | Christa Beckmann1,5 | Sophie Rome6 | Peter A. Biro1 | Robert Gatenby7 | Joel Brown7 | Luis Almeida8 | Frédéric Thomas3

Abstract

While obesity is widely recognized as a risk factor for cancer, survival among patients with cancer is often higher for obese than for lean individuals. Several hypotheses have been proposed to explain this “obesity paradox,” but no consensus has yet emerged. Here, we propose a novel hypothesis to add to this emerging debate which suggests that lean healthy persons present conditions unfavorable to malignant transformation, due to powerful natural defenses, whereby only rare, but aggressive neoplasms can emerge and develop. In contrast, obese persons present more favorable conditions for malignant transformation, because of several weight-associated factors and less efficient natural defenses, leading to a larger quantity of neoplasms comprising both nonaggressive and aggressive ones to regularly emerge and progress. If our hypothesis is correct, testing it would require consideration of the raw quantity, not the relative frequency, of aggressive cancers in obese patients compared with lean ones. We also discuss the possibility that in obese persons, nonaggressive malignancies may prevent the subsequent progression of aggressive cancers through negative competitive interactions between tumors.

KEYWORDS
cancer, evolution, obesity, selective filter
It is increasingly established that excess body fat is associated with higher cancer risk (Calle, Rodriguez, Walker-Thurmond, & Thun, 2003; IARC, 2002; Marmot, Atinmo, Byers, & Chen, 2007). However, it is also commonly found that elevated body mass index (BMI; i.e., above 25 kg/m², Arnold et al., 2016) is associated with improved survival among cancer patients compared to lean subjects (see Lennon, Sperrin, Badrick, & Renehan, 2016 and Wang et al., 2018 for recent reviews). This conflicting finding, termed the “obesity paradox,” is currently attracting increasing attention from oncologists and epidemiologists (Caan & Kroenke, 2017; Gonzalez, Pastore, Orlandi, & Heymsfield, 2014; Gupta, 2016; Mayeda & Glymour, 2017; Strulov Shachar & Williams, 2017). The “obesity paradox” has been demonstrated in patients with lymphoma, leukemia, colorectal, endometrial, thyroid, renal, and lung cancers (Caan & Kroenke, 2017; Zhang, Liu, Shao, & Zheng, 2017). For reasons that are unclear the list of cancers that apparently fall under the obesity paradox is not necessarily the same as those cancers most commonly observed in obese persons: esophagus (adenocarcinoma only), colon and rectum, liver, gallbladder, pancreas, kidney, advanced prostate, post-menopausal female breast, endometrium, and ovary cancers (Whiteman & Wilson, 2016).

Recent studies have suggested various phenomena that might explain the obesity paradox, but these have mainly focused on methodological problems including the crudeness of BMI as an obesity measure, confounds with other factors, detection bias, and reverse causality and collider-stratification bias (Lennon et al., 2016; Park, Peterson, & Colditz, 2018). While these methodological limitations are possible, they are however unlikely to fully account for the observed findings (Caan & Kroenke, 2017).

In contrast to these explanations which suggest that the “obesity paradox” is an artifact of the data and its analysis and not a causal or functional link, we put forward here a mechanistic explanation for why this paradox might arise. We propose that the effects of obesity on oncogenic process dynamics coupled with its negative effect on the efficiency of natural defense mechanisms could wrongly suggest that obesity has a protective effect. Apart from this possible misinterpretation, it remains also possible that in obese patients the same processes favor the early emergence of less aggressive tumors that subsequently prevent the development and growth of more aggressive ones.

While we often distinguish between people who do and do not have cancer, the reality is that virtually every individual develops small tumors in the body by the time they reach their sixth or seventh decade of life (Bissell & Hines, 2011; Folkman & Kalluri, 2004). The reasons why these lesions sometimes progress to clinical diseases are currently not fully understood, but at least partially depend on the efficiency of protective mechanisms to prevent the microscopic colonies of malignant cells from becoming lethal invasive tumors (Harris, Schiffman, & Boddy, 2017). There is also strong evidence indicating that an excess of fat negatively impacts immune function and host defenses in obese individuals (Bandaru, Rajkumar, & Nappanveettil, 2013; Meckenstock & Therby, 2015; Milner & Beck, 2012), a process that is also likely to accelerate malignant progression (Bindea, Mlecnik, Fridman, Pagès, & Galon, 2010; Jacqueline, Biro, et al., 2016; Jacqueline, Bourfia, et al., 2016). Ducasse et al. (2015) also provided compelling evidence that cancer can be viewed as a particular manifestation of a quasi-universal ecological process that is the proliferation of profiteering phenotypes in disturbed systems with unused resources. With the alteration of the internal ecosystem associated with obesity (e.g., increased levels of endogenous hormones, the contribution of abdominal obesity to gastro-esophageal reflux and esophageal adenocarcinoma, inflammatory responses), together with abundant unused resources, a higher number and diversity of malignancies progress and become clinically evident (Nunez, Hursting, Yakar, Fowler, & Vinson, 2009; Price, Cavazos, Angel, Hursting, & deGraffenried, 2012). Recently Wang et al. (2018) demonstrated that obesity often results in increased immune aging, tumor progression, and PD-1-mediated T-cell dysfunction partially driven by leptin. Thus, because obesity has both proliferative effects on the dynamics of oncogenesis and negative effects on protective mechanisms, it is expected that obese persons should be prone to malignant problems that are both frequent and highly variable in their level of aggression.

In contrast to obese persons, we predict that lean healthy persons are expected to be prone to malignant growths that are rare, but more likely to be aggressive—lean persons generally present unfavorable conditions for malignant progression and possess more protective mechanisms than obese persons. Together, these protective factors are expected to select for highly aggressive cells (i.e., that overwhelm defenses), whereas obese persons are expected to show more numerous but less aggressive neoplasia. While the global picture suggests that obesity could on average protect from developing aggressive cancers (Lennon et al., 2016), we suggest that this might be just an misinterpretation. The lack of aggressive and likely malignant neoplasia could explain the high incidence and multiplicity of cancer on the one hand, and higher survivorship on the other. Therefore, the true test to resolve the obesity paradox would be to consider the raw quantity, not the relative frequency of aggressive versus nonaggressive cancer cells between obese and normal weight persons. In accordance with our hypothesis, it has for example been demonstrated that renal cell cancers are often less aggressive in the obese (Albiges et al., 2016; Hakimi et al., 2013; Nishihara et al., 2015). Further studies are, however, necessary to fully determine why several obesity-related cancers (see above) do not adhere to the obesity paradox, and hence deviate from the logic of our hypothesis. Similarly, further studies also need to explore the extent to which the enhanced survival in the obese is attributable to the reduced aggressivity of malignant cells and/or to the fact that those cells are more sensitive to treatment.

Another mechanism contributing to this apparent “paradox” may involve inhibitory effects of abundant nonaggressive neoplasia on those likely to become aggressive. That is, in obese patients the faster dynamics of oncogenesis together with lower defenses (see above) favor, at least sometimes, the early development of more benign tumors that exert negative effects on subsequent neoplasm formation—thus, emergence of aggressive tumors could be reduced. This could, for instance, be the case if aggressiveness in cancer is associated with the number of functional/driver mutations in a tumor.
(Maley et al., 2006), such that less aggressive tumors are more likely to appear first. This hypothesis is in fact an extrapolation of the phenomenon of “concomitant resistance” where the primary tumor prevents growth of metastasis (Benzeckry, Gandolfi, & Hahnfeldt, 2014; Guba et al., 2001; Ruggiero et al., 2012).

Following the emergence of premalignant lesions, the survival of cancer clusters relies on increased production of angiogenesis stimulators, such as vascular endothelial growth factor (VEGF), that attract nutrient and oxygen providing blood vessels to the growing tumors (Bremnes, Camps, & Sirera, 2006; Carmeliet, 2005; Peterson et al., 2012). If two tumors induce production of angiogenesis stimulators, it is likely that eventually a threshold will be reached, such that the host would respond with increased production of angiogenesis inhibitors (e.g., platelet factor 4 [PF-4], thrombospondin-1 [TSP1], and endostatin), to counteract systemic increase in angiogenesis stimulators, which may be sufficient to restrict the growth of the smaller secondary tumors (Kareva, 2017). Interestingly, TSP1 is over-expressed in obese patients (Varma et al., 2008), and this phenomenon may contribute to the obesity paradox. While more easily initiated, the TSP1 response in obese individuals may contribute to less aggressive and life-threatening cancers. This scenario, which could explain the obesity paradox, also suggests that if the less aggressive tumors are surgically resected in obese patients, it could cause systemic decrease in the level of angiogenesis stimulators, which would be followed by decrease in the levels of angiogenesis inhibitors as the host’s body restores homeostasis of angiogenesis regulators. This decrease could subsequently provide a “window of opportunity” for other, more aggressive, tumors to start growing (Demicheli, Retsky, Hrushesky, Baum, & Gukas, 2008). This is an additional reason why understanding whether or not an obesity paradox exists and its eventual causes are crucial. As suggested above, postulated mechanisms include angiogenesis, but immunity and even tyrosine isomers could play a role. For instance, Ruggiero et al. (2012) found in three murine models that show concomitant resistance (i.e., tumor-bearing hosts are resistant to the growth of secondary tumor implants and metastasis) to both meta-tyrosine and ortho-tyrosine inhibited tumor growth, and even sometimes blocked metastasis. Beyond the obesity context, the reasoning presented in this paper could be extended to the population in general, whether obese or not. Indeed, by extension, it is expected that cancers in people with a healthy lifestyle should, all things being equal, be rarer but more aggressive than in persons with an unhealthy lifestyle. Further research should be conducted to investigate this question and to determine the nature of the interactions between co-occurring tumors throughout the lifetime of people.

ACKNOWLEDGEMENTS

This work was supported by the ANR (Blanc project TRANSCAN), by the CNRS (INEE), by an International Associated Laboratory Project France/Australia, and by an Australian Academy of Science, FASIC Early Career Fellowship to BU. We would like to thank two anonymous referees for their relevant suggestions.

CONFLICT OF INTEREST

None declared.

ORCID

Beata Ujvari https://orcid.org/0000-0003-2391-2988
Christa Beckmann https://orcid.org/0000-0002-7904-7228
Frédéric Thomas https://orcid.org/0000-0003-2238-1978

REFERENCES

Albiges, L., Hakimi, A. A., Xie, W., McKay, R. R., Simantov, R., Lin, X., ... Choueiri, T. K. (2016). Body mass index and metastatic renal cell carcinoma: Clinical and biological correlations. *Journal of Clinical Oncology*, 34(30), 3655–3663. https://doi.org/10.1200/JCO.2016.66.7311
Arnold, M., Leitzmann, M., Freising, H., Bray, F., Romieu, I., Renehan, A., & Soerjomataram, I. (2016). Obesity and cancer: An update of the global impact. *Cancer Epidemiology, 41*, 8–15. https://doi.org/10.1016/j.canep.2016.01.003
Bandaru, P., Rajkumar, H., & Nappanveettil, G. (2013). The impact of obesity on immune response to infection and vaccine: An insight into plausible mechanisms. *Endocrinology and Metabolic Syndrome*, 2, 113.
Benzeckry, S., Gandolfi, A., & Hahnfeldt, P. (2014). Global dormancy of metastases due to systemic inhibition of angiogenesis. *PloS One*, 9(1), e84249–e84249.
Bindea, G., Mlecnik, B., Fridman, W.-H., Pagès, F., & Galon, J. (2010). Natural immunity to cancer in humans. *Current Opinion in Immunology*, 22(2), 215–222. https://doi.org/10.1016/j.coi.2010.02.006
Bissell, M. J., & Hines, W. C. (2011). Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. *Nature Medicine*, 17(3), 320–329. https://doi.org/10.1038/nm.2328
Bremnes, R. M., Camps, C., & Sirera, R. (2006). Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. *Lung Cancer*, 51(2), 143–158. https://doi.org/10.1016/j.lungcan.2005.09.005
Caan, B. J., & Kroenke, C. H. (2017). Next steps in understanding the obesity paradox in cancer. *Cancer Epidemiology Biomarkers & Prevention*, 26(1), 12. https://doi.org/10.1158/1055-9965.EPI-16-0764
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *New England Journal of Medicine*, 348(17), 1625–1638.
Carmeliet, P. (2005). VEGF as a key mediator of angiogenesis in cancer. *Oncology*, 69(Suppl 3), 4–10.
Demicheli, R., Retsky, M. W., Hrushesky, W. J. M., Baum, M., & Gukas, I. D. (2008). The effects of surgery on tumor growth: A century of proposed role of the microenvironment in restraining cancer progression. *Nature Medicine*, 17(3), 320–329. https://doi.org/10.1038/nm.2328
Ducasse, H., Arni, A., Vittecoq, M., Daoust, S. P., Ujvari, B., Jacqueline, C., ... Thomas, F. (2015). Cancer: An emergent property of disturbed evolutionary Applications, 8(6), 527–540. https://doi.org/10.1111/evo.12232
Folkman, J., & Kalluri, R. (2004). Cancer without disease. *Nature*, 427(6977), 787–787. https://doi.org/10.1038/427787a
Gonzalez, M. C., Pastore, C. A., Orlandi, S. P., & Heymsfield, S. B. (2014). Obesity paradox in cancer: New insights provided by body composition. American Journal of Clinical Nutrition, 99(5), 999–1005. https://doi.org/10.3945/ajcn.113.071399

Guba, M., Cernaianu, G., Koehl, E. K., Jauch, K.-W., Anthuber, M., ... & Steinbauer, M. (2001). A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Research, 61(14), 5575.

Gupta, S. (2016). Obesity: The fat advantage. Nature, 537(7620), S100–S102.

Hakimi, A. A., Furberg, H., Zabor, E. C., Jacobsen, A., Schultz, N., Ciriello, G., ... Russo, P. (2013). An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. Journal of the National Cancer Institute, 105(24), 1862–1870. https://doi.org/10.1093/jnci/djt310

Harris, V. K., Schiffman, J. D., & Boddy, A. M. (2017). Evolution of cancer defense mechanisms across species. In B. Ujvari, B. Roche, & F. Thomas (Eds.), Ecology and evolution of cancer. Amsterdam, The Netherlands: Elsevier.

IARC. (2002). Weight control and physical activity, IARC Vol. 6: IARC handbook of cancer prevention. Lyon, France: International Agency for Research on Cancer.

Jacqueline, C., Biro, P. A., Beckmann, C., Moller, A. P., Renaud, F., Sorci, G., ... & Thomas, F. (2016). Cancer: A disease at the crossroads of tradeoffs. Evolutionary Applications, 10, 215–225.

Jacqueline, C., Bourflia, Y., Hbid, H., Sorci, G., Thomas, F., & Roche, B. (2016). Interactions between immune challenges and cancer cells proliferation: Timing does matter! Evolution, Medicine, and Public Health, 2016(1), 299–311.

Karpev, I. (2017). Cancer as a disease of homeostasis: An angiogenesis perspective. In B. Ujvari, B. Roche, & F. Thomas (Eds.), Ecology and evolution of cancer (229–235). Amsterdam, The Nethelands: Elsevier.

Lennon, H., Sperrin, M., Badrick, E., & Renehan, A. G. (2016). The obesity paradox in cancer: A review. Current Oncology Reports, 18(9), 56. https://doi.org/10.1007/s11912-016-0539-4

Maley, C. C., Galipeau, P. C., Finley, J. C., Jon Wongsurawat, V., Li, X., Sanchez, C. A., ... Reid, B. J. (2006). Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nature Genetics, 38(4), 468–473. https://doi.org/10.1038/ng1768

Marmot, M., Atinmo, T., Byers, T., & Chen, J. (2007). Food, nutrition, physical activity, and the prevention of cancer: A global perspective. In World Cancer Research Fund / American Institute for Cancer Research (AICR) Expert Reports. 2. Washington, DC.

Mayeda, E. R., & Glymour, M. M. (2017). The obesity paradox in survival after cancer diagnosis: Tools for evaluation of potential bias. Cancer Epidemiology Biomarkers & Prevention, 26(1), 17–20. https://doi.org/10.1158/1055-9965.EPI-16-0559

Meckenstock, R., & Therby, A. (2015). Modifications de l’immunité dans l’obésité: Impact sur le risque infectieux. La Revue De Médecine Interne, 36(11), 760–768. https://doi.org/10.1016/j.revmed.2015.07.013

Milner, J. J., & Beck, M. A. (2012). The impact of obesity on the immune response to infection. Proceedings of the Nutrition Society, 71(2), 298–306. https://doi.org/10.1079/SPN029665112000158

Nishihara, R., VanderWeele, T. J., Shibuya, K., Mittenman, M. A., Wang, M., Field, A. E., ... & Ogino, S. (2015). Molecular pathological epidemiology gives clues to paradoxical findings. European Journal of Epidemiology, 30(10), 1129–1135. https://doi.org/10.1007/s10654-015-0088-4

Nunez, N. P., Hursting, S. D., Yakar, S., Fowler, D., & Vinson, C. (2009). Obesity provides a permissive milieu in inflammation-associated carcinogenesis: Analysis of insulin and IGF pathways. In S. V. Kozlov (Ed.), Inflammation and cancer: Methods and protocols: Volume 2: Molecular analysis and pathways (pp. 29–38). Totowa, NJ: Humana Press.

Park, Y., Peterson, L. L., & Colditz, G. A. (2018). The plausibility of obesity paradox in cancer—point. Cancer Research, 78(8), 1898. https://doi.org/10.1158/0008-5472.CAN-17-3043

Peterson, J. E., Zurakowski, D., Italiano, J. E. Jr., Michel, L. V., Connors, S., Oenick, M., ... & Folkman, J. (2012). VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis, 15(2), 265–273. https://doi.org/10.1007/s10456-012-9259-z

Price, R. S., Cazavos, D. A., De Angel, R. E., Hursting, S. D., & deGraffenried, L. A. (2012). Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer and Prostatic Diseases, 15(2), 135–143. https://doi.org/10.1038/pcc.2011.54

Ruggiero, R. A., Bruzzo, J., Chiarella, P., Bustuobad, O. D., Meiss, R. P., & Pasqualini, C. D. (2012). Comitomitant tumor resistance: The role of tyrosine isomers in the mechanisms of metastases control. Cancer Research, 72(5), 1043. https://doi.org/10.1158/0008-5472.CAN-11-2964

Strulov Shachar, S., & Williams, G. R. (2017). The obesity paradox in cancer—moving beyond BMI. Cancer Epidemiology Biomarkers & Prevention, 26(1), 13. https://doi.org/10.1158/1055-9965.EPI-16-0439

Varma, V., Yao-Borengasser, A., Bodles, A. M., Rasouli, N., Panahvand, B., Nolan, G. T., ... & Kern, P. A. (2008). Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes, 57(2), 432. https://doi.org/10.2337/db07-0840

Wang, Z., Aguilar, E. G., Luna, J. I., Dunai, C., Khuat, L. T., Le, C. T., ... & Monjazeb, A. M. (2018). Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nature Medicine, 25, 141–151.

Whiteman, D. C., & Wilson, L. F. (2016). The fractions of cancer attributable to modifiable factors: A global review. Cancer Epidemiology, 44, 203–221. https://doi.org/10.1016/j.canep.2016.06.013

Zhang, X., Liu, Y., Shao, H., & Zheng, X. (2017). Obesity paradox in lung cancer prognosis: evolving biological insights and clinical implications. Journal of Thoracic Oncology, 12(10), 1478–1488. https://doi.org/10.1016/j.jtho.2017.07.022

How to cite this article: Ujvari B, Jacqueline C, Misse D, et al. Obesity paradox in cancer: Is bigger really better? Evol Appl. 2019;12:1092–1095. https://doi.org/10.1111/eva.12790